Catalyst Biosciences to Present at the Cowen Healthcare Conference
February 24 2020 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced
that Nassim Usman, Ph.D., president and chief executive
officer of Catalyst Biosciences, will present a corporate overview
at the Cowen Healthcare Conference at 8:40 a.m. ET on Tuesday,
March 3, 2020, in Boston.
To access a live webcast of the presentation, please
visit http://wsw.com/webcast/cowen57/cbio/.
An archived webcast of the presentation will be available for 90
days on the Events and Presentations section on the Company’s
website.
About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical
company focused on addressing unmet needs in rare diseases and
systemic complement mediated disorders. Our protease engineering
platform includes development programs in hemophilia and a research
program on subcutaneous (SQ) systemic complement inhibitors. Our
engineered coagulation factors are designed to overcome the
significant limitations of current IV treatment options, facilitate
prophylaxis, and ultimately deliver substantially better outcomes
for patients using SQ dosing. Our lead asset, MarzAA (FVIIa) has
successfully completed Phase 2 development, reducing the annualized
bleed rate (ABR) in individuals with hemophilia A or B with
inhibitors by >90%. Our second hemophilia asset, DalcA (FIX) is
completing a Phase 2b clinical trial for the prophylactic treatment
of hemophilia B and has achieved FIX levels from 12-27%. We also
have a global license and collaboration agreement with Biogen for
the development and commercialization of pegylated CB 2782 (anti-C3
protease) for the potential treatment of geographic atrophy
associated dry age-related macular degeneration.
For more information, please visit
www.catalystbiosciences.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties.
Forward-looking statements include statements about the potential
uses and benefits of Catalyst’s products in development to address
hemophilia indications and other rare bleeding disorders, including
the potential benefits of SQ dosing and about Catalyst’s
collaboration with Biogen. Actual results or events could differ
materially from the expectations disclosed in the forward-looking
statements as a result of various important factors, including, but
not limited to, the risk that trials and studies may be delayed and
may not have satisfactory outcomes, that additional human trials
will not replicate the results from earlier trials, that potential
adverse effects may arise from the testing or use of MarzAA or
DalcA, including the generation of antibodies, which has been
observed in patients treated with DalcA, the risk that costs
required to develop or manufacture the Company’s products will be
higher than anticipated, the risk that Biogen will terminate the
collaboration, competition and other factors that affect our
ability to establish collaborations on commercially reasonable
terms and other risks described in the “Risk Factors” section of
the Company’s annual report filed with the Securities and Exchange
Commission on February 20, 2020, and in other filings with the
Securities and Exchange Commission. The Company does not assume any
obligation to update any forward-looking statements, except as
required by law.
Contact:Ana Kapor Catalyst Biosciences, Inc.
investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024